Table 1.
Efficacy and Safety of Immunotherapy in Pediatric Cancer Patients.
| Reference | Age | Number | Tumor types | Immunotherapy | Key outcomes |
|---|---|---|---|---|---|
| Geoerger et al 39 | 13 Y | N = 155 | Relapsed or refractory Solid tumor or lymphoma |
Pembrolizu-mab |
Efficacy: HL (n = 15) CR 2 (13%) PR 7 (47%) PD 3 (20%) other tumor type (n = 136) CR 0 PR 8 (6%) PD 74 (54%) Safety: immune-related: grade 1-2, n = 30 (19%) grade 3, n = 2 (1%) grade 5, n = 1 (<1%) |
| Marjanska et al 40 | 7 Y | N = 1 | Recurrent metastatic melanoma | Pembrolizu-mab |
Efficacy: CR lasting 12 months Safety: irAEs Arthritis, uveitis |
| AlHarbi et al 41 | 5 Y | N = 1 | Refractory glioblasto-ma | Nivolumab |
Efficacy: Durable response lasting 10 months Safety: No adverse reactions |
| Merchant et al 42 | 13.4 Y | N = 33 | Melanoma/Sarcoma/Renal carcinoma/bladder carcinoma/Neuroblastoma | Ipilimumab |
Efficacy: No objective tumor regressions Safety: Patients with irAEs n = 18 (55%) |
| Davis et al 43 | 14Y | N = 85 | Relapsed or refractory solid tumor or lymphoma | Nivolumab |
Efficacy: HL (n = 10) CR 1 (10%) PR 2 (20%) SD 5 (50%) Safety: Patients with grade 3-4 irAEs n = 27/75 (36%) |
| Geoerger et al 44 | 14Y | N = 87 | solid tumor or HL or NHL | Atezolizumb |
Efficacy: PR 4 (5%) SD 10 (11%) PD 63 (72%) Safety: Patients with irAE n = 57 (66%) |
Abbreviations: CR, Complete response; EFS, Event-free survival; HL, Hodgkin’s lymphoma; irAEs, immune-related adverse events; NHL, non-Hodgkin’s lymphoma; OS, overall survival; PR, partial response; PD, progressive disease; SD, stable disease.